These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662 [TBL] [Abstract][Full Text] [Related]
6. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396 [TBL] [Abstract][Full Text] [Related]
7. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259 [TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290 [TBL] [Abstract][Full Text] [Related]
9. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060 [TBL] [Abstract][Full Text] [Related]
14. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up. Choe HJ; Moon JH; Kim W; Koo BK; Cho NH Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077 [TBL] [Abstract][Full Text] [Related]
16. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis. Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681 [TBL] [Abstract][Full Text] [Related]
17. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259 [TBL] [Abstract][Full Text] [Related]
18. Practice Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN). Sood V; Alam S; Nagral A; Srivastava A; Deshmukh A; Bavdekar A; Acharyya BC; Geetha SM; Gupte G; Bhatia I; Tiwari K; Bharadia L; Sathiyasekaran M; Kaur P; Khanna R; Shrivastava R; Poyekar S; Pandey S; Ramakrishna SH; Kinjawadekar U; Borkar V; Sivaramakrishnan VM; Kohli R; Matthai J; Dhawan A Indian Pediatr; 2024 Sep; ():. PubMed ID: 39297398 [TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. Moon JH; Jeong S; Jang H; Koo BK; Kim W EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905 [TBL] [Abstract][Full Text] [Related]
20. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Song R; Li Z; Zhang Y; Tan J; Chen Z Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]